Intra-Cellular Therapies, Inc. (ITCI)
NASDAQ: ITCI · IEX Real-Time Price · USD
68.80
-1.54 (-2.19%)
At close: May 3, 2024, 4:00 PM
69.80
+1.00 (1.45%)
After-hours: May 3, 2024, 6:16 PM EDT
Intra-Cellular Therapies Revenue
In the year 2023, Intra-Cellular Therapies had annual revenue of $464.37M with 85.51% growth. Revenue in the quarter ending December 31, 2023 was $132.10M with 50.34% year-over-year growth.
Revenue (ttm)
$464.37M
Revenue Growth
+85.51%
P/S Ratio
14.34
Revenue / Employee
$761,262
Employees
610
Market Cap
6.66B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 464.37M | 214.06M | 85.51% |
Dec 31, 2022 | 250.31M | 166.51M | 198.69% |
Dec 31, 2021 | 83.80M | 60.99M | 267.35% |
Dec 31, 2020 | 22.81M | 22.75M | 37,537.14% |
Dec 31, 2019 | 60.61K | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 245.84K | -84.87K | -25.66% |
Dec 31, 2016 | 330.70K | 239.34K | 261.96% |
Dec 31, 2015 | 91.36K | -485.94K | -84.17% |
Dec 31, 2014 | 577.30K | -2.16M | -78.91% |
Dec 31, 2013 | 2.74M | -380.99K | -12.22% |
Dec 31, 2012 | 3.12M | -20.24M | -86.65% |
Dec 31, 2011 | 23.36M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Elanco Animal Health | 4.42B |
The Ensign Group | 3.85B |
Jazz Pharmaceuticals | 3.84B |
Exelixis | 1.85B |
HealthEquity | 999.59M |
Ionis Pharmaceuticals | 787.65M |
Blueprint Medicines | 282.21M |
Revolution Medicines | 11.58M |
ITCI News
- 4 days ago - Intra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and Webcast - GlobeNewsWire
- 10 days ago - Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 17 days ago - Intra-Cellular Therapies Prices Public Offering of Common Stock - GlobeNewsWire
- 18 days ago - Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 18 days ago - Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder - GlobeNewsWire
- 6 weeks ago - Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes - GlobeNewsWire
- 2 months ago - Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Intra-Cellular Therapies to Present at the 44th Annual TD Cowen Health Care Conference - GlobeNewsWire